The influence of verapamil on renal function in patients treated with cisplatin.

Abstract

Nine patients with testicular cancer were treated with four platinum containing chemotherapy courses. In order to prevent cisplatin (CDDP)-induced nephrotoxicity, verapamil, a calcium entry blocker, was added to the chemotherapeutic regimen. Renal function studies, consisting of the measurement of the effective renal plasma flow (ERPF) and the glomerular filtration rate (GFR), were performed before, during and after the first dose of CDDP, at the end of the first course and at the end of the fourth course of chemotherapy. The results were compared with the results obtained previously in CDDP-treated patients not receiving verapamil. The initial decrease in ERPF during and after the first CDDP infusion was completely prevented by verapamil. Despite continuation of verapamil throughout all four courses, it failed to reduce the ultimate fall in GFR.

Statistics

0200400600'94'97'00'03'06'09'12'15
Citations per Year

229 Citations

Semantic Scholar estimates that this publication has 229 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Offerman1985TheIO, title={The influence of verapamil on renal function in patients treated with cisplatin.}, author={Joop J. G. Offerman and Sybren Meijer and Dirk Th Sleijfer and Nanno H. Mulder and A . J . M . Donker and H Schraffordt koops and G K van der Hem}, journal={Clinical nephrology}, year={1985}, volume={24 5}, pages={249-55} }